Company: VRCA
Filing Date: 2025-04-30
Form Type: DEFR14A
Source: 0001193125-25-105562
Chunk: 47

Company: Verrica Pharmaceuticals Inc.
Filing Date: 2025-04-30
Form: DEFR14A
Chunk 47
---
G filed on February 12, 2025 by entities and individuals associated with Caligan Partners LP (“Caligan”). Consists of (a) 7,429,687 shares of common stock and (b) 1,933,267 shares of common stock issuable upon exercise of warrants (the “Caligan Warrants”) held by Caligan Partners Master Fund LP (the “Caligan Master Fund”), which due to the Caligan Beneficial Ownership Limitation (as defined below) is the maximum number of shares that could be issued upon exercise of the Caligan Warrants within 60 days of April 1, 2025. Pursuant to the terms of the Caligan Warrants, the holder of such Caligan Warrants does not have the right to exercise any portion of the Caligan Warrants, to the extent that, after giving effect to the attempted exercise set forth in a notice of exercise, such holder, together with such holder’s affiliates and any other person whose beneficial ownership of |

33

| (4) | This information has been obtained from a Schedule 13G/A filed on February 14, 2025 by entities and individuals associated with Perceptive Advisors LLC (“Perceptive Advisors”). Consists of (a) 3,249,669 shares of common stock and (b) 1,481,481 shares of common stock issuable upon exercise of warrants within 60 days of April 1, 2025 held by Perceptive Life Sciences Master Fund, Ltd. (the “Perceptive Master Fund”). Perceptive Advisors serves as the investment manager to the Perceptive Master Fund and may be deemed to beneficially own the securities directly held by the Perceptive Master Fund. Joseph Edelman is the managing member of Perceptive Advisors and may be deemed to beneficially own the securities directly held by the Perceptive Master Fund. The address of Perceptive Advisors is 51 Astor Place, 10th Floor, New York, NY 10016. |

| (5) | Consists of (a) 1,873,800 shares of common stock and (b) 1,123,594 shares of common stock issuable upon the exercise of warrants within 60 days of April 1, 2025. |

| (6) | Consists of (a) 889,881 shares of common stock, (b) 267,500 shares of common stock issuable upon the exercise of options within 60 days of April 1, 2025 and